Abstract Overview: Impact of MET Inhibitors in METdel14 NSCLC Patients - 102164

Spotlight
Video

Abstract Overview: Impact of MET Inhibitors in METdel14 NSCLC Patients

Loading........
Description: Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute gives an overview of his abstract, Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC), at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Shared By : AnnualMeeting2017
Posted on : 06/13/17
Added : 7 months ago



Recommended

Nothing found.

More From AnnualMeeting2017

Nothing found.